Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Net income
Johnson & Johnson's net income for fiscal 2025 was $26.8B, up 90.6% from $14.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $21.0B. Over the past ten years it has ranged from $1.3B (fiscal 2017) to $35.2B (fiscal 2023); the current reading is higher than 91% of that period. Johnson & Johnson ranks 2nd of 21 Drug Manufacturers General companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $26.8B | 90.56% |
| FY2024 | $14.1B | (59.99%) |
| FY2023 | $35.2B | 95.94% |
| FY2022 | $17.9B | (14.07%) |
| FY2021 | $20.9B | 41.89% |
| FY2020 | $14.7B | (2.68%) |
| FY2019 | $15.1B | (1.16%) |
| FY2018 | $15.3B | 1,076.69% |
| FY2017 | $1.3B | (92.14%) |
| FY2016 | $16.5B | 7.34% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $5.5B | 5.71% |
| Mar 2026 | $5.2B | 2.33% |
| Dec 2025 | $5.1B | (0.70%) |
| Sep 2025 | $5.2B | (6.95%) |
| 42 more quarters | Free account |
Against its own ten years
Low $1.3B
High $35.2B
Ten-year median
$15.4B
Current reading's percentile
91
Net income against peers
| Company | Net income |
|---|---|
| LLY Eli Lilly and Company compare | $26.7B |
| JNJ Johnson & Johnson | $21.0B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| AMGN Amgen Inc. compare | $8.7B |
| ABBV AbbVie Inc. compare | $6.3B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on JNJ
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement